Preclinical models demonstrated improved hair growth compared to minoxidil. As we advance ABS-201, we envision a straightforward path to clinical development and have assembled a robust network of renowned hair...
dividend growth. We’re on a path to increase mid-cycle adjusted EBITDA by 40% to $14 billion by 2030. In addition, 75% of this growth will be outside of Refining. We expect this growth and more stable cash...
